TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8016555
Drug: 2.2 mM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.2 mM CHX mouthrinses used twice daily
Study: 8016555
Drug: 11.9 mM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.9 mM NaF rinses used daily
Study: 8016555
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CHX and NaF rinses
Study: 30253197
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vortioxetine
Study: 30253197
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg vortioxetine
Study: 23199977
Drug: Inhaled procaterol
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled procaterol before exercise
Study: 23199977
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no inhaled procaterol)
Study: 20391086
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued daily life)
Study: 18795931
Drug: Patch Test
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch Test with MDBGN
Study: 18795931
Drug: Accumulated ROAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accumulated ROAT doses (1, 2, and 3 weeks) with MDBGN
Study: 4076354
Drug: Daily structured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily structured physical exercise for 10 weeks
Study: 4076354
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily inspiratory muscle training by resistive breathing for 10 weeks
Study: 4076354
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo training for 10 weeks
Study: 29428926
Drug: Articulatory costal
Normalized name: Coastal Water-hyssop Whole
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articulatory costal manual therapy (AC group)
Study: 29428926
Drug: Neurolymphatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurolymphatic therapy (NL group)
Study: 29428926
Drug: Articulatory spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articulatory spinal manual therapy (AS group)
Study: 22137666
Drug: Once‐per‐week EPO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once‐per‐week EPO, 1200 U/kg/dose, subcutaneously for 4 weeks
Study: 22137666
Drug: 3‐times‐a‐week EPO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐times‐a‐week EPO, 400 U/kg/dose, subcutaneously for 4 weeks
Study: 15650312
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 60 mg twice daily (bid)
Study: 11291084
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of synthetic mutant ras peptides with granulocyte-macrophage colony-stimulating factor as adjuvant
Study: 9384020
Drug: Aerosolized oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized oxygen with antibacterial, antiphlogistic drugs, expectorants, antispastic and antiasthmatic drugs
Study: 9384020
Drug: Convenient simple
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convenient simple aerosolized oxygen inhalation
Study: 8202964
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 to 40 mg/d) for 3 and 6 weeks
Study: 2239815
Drug: Yomeishu (YMS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yomeishu (YMS) 20 ml twice a day before meals for 12 weeks
Study: 1093464
Drug: Dimethyl sulfoxide
Normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dimethyl sulfoxide therapy (DAT)
Study: 27805571
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir 800 mg once a day for 6 days
Study: 27805571
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir 400 mg twice daily for 6 days
Study: 26114120
Drug: Weight Achievement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight Achievement and Intensive Treatment (Why WAIT) program, a 12-week intensive program for diabetes weight management
Study: 23102873
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BTA injection).
Study: 11240959
Drug: Atopy patch
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopy patch test (APT) combined with specific IgE measurement
Study: 11240959
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of positive APT results and specific IgE measurement
Study: 28049642
Drug: Clofarabine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine (10 mg/m2 on days 1-5 of each of both cycles)
Study: 25982338
Drug: Propranolol combined
Normalized name: propranolol and other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol combined with oral prednisolone for the initial 2 weeks
Study: 23063625
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine plus triamcinolone 40mg IA injection
Study: 21750266
Drug: ALA (1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA (1,800 mg/day) for 2 weeks
Study: 21750266
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion with ALA pretreatment
Study: 21750266
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion without ALA pretreatment
Study: 19401659
Drug: Propofol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.2 mg kg(‐1) bolus, followed by infusion at 2 mg kg(‐1) h(‐1))
Study: 19401659
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC, infusion at 5 mg kg(‐1) h(‐1))
Study: 15290395
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative treatment (Control)
Study: 11894980
Drug: Oral combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combined continuous hormone replacement therapy (HRT) with Kliogest (oestradiol 2 mg, norethisterone 1 mg)
Study: 9469797
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg perindopril administered at 0900 h
Study: 9469797
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg perindopril administered at 2100 h
Study: 3074777
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg twice a day
Study: 28545321
Drug: Intranasal MLV
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal MLV vaccine (containing BoHV-1, BRSV, BPIV-3)
Study: 28545321
Drug: Subcutaneous MLV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous MLV vaccine (containing BVDV-1, BVDV-2, BoHV-1, BRSV, BPIV-3)
Study: 28545321
Drug: Intranasal MLV
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal MLV vaccine
Study: 23062631
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% permethrin cream and a comprehensive scabies control programme including hygiene monitoring and health education classes.
Study: 21906391
Drug: amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine (5 mg/day)
Study: 26577506
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Study: 3883767
Drug: Nifedipine in
Normalized name: nifedipine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine in cardioplegic solution (average dose 407 +/- 22 micrograms at one center; 476 +/- 22 micrograms at another center)
Study: 29471930
Drug: Methadone Maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone Maintenance Treatment (MMT)
Study: 29149381
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education programme (DTTP) for conventional insulin therapy in outpatient group
Study: 29149381
Drug: Patient education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education programme (DTTP) for conventional insulin therapy in inpatient group
Study: 19037084
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg QD
Study: 19037084
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg BID
Study: 19037084
Drug: Lisinopril 40
Normalized name: lisinopril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 40 mg QD
Study: 17959549
Drug: Bronchovaxom treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchovaxom treatment (3.5 mg daily for 10 days every month for 3 months)
Study: 17959549
Drug: Budesonide aerosol
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aerosol (200 microg once or twice daily for 3 months)
Study: 17959549
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment group (budesonide)
Study: 15547426
Drug: Bilateral electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral electrical stimulation with Nucleus 24 cochlear implant
Study: 9551877
Drug: 4-day oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day oral salt load (150 mmol NaCl extra per day)
Study: 1833903
Drug: Enoximone therapy
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone therapy
Study: 6315447
Drug: Natural and
Normalized name: Natural and artifical flavoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural and synthetic oestrogen administration
Study: 25046547
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd)
Study: 25046547
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg/qd)
Study: 22269042
Drug: DHA-containing functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-containing functional food (300 mg DHA, 92 kcal) consumed an average of 5 days/week from 24 weeks gestation until delivery
Study: 20201608
Drug: Ethinylestradiol (EE)
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol (EE) 30 microg/DRSP 3 mg (n = 573)
Study: 20201608
Drug: Ethinylestradiol (EE)
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol (EE) 30 microg/DRSP 3 mg
Study: 18684735
Drug: Recombinant follicle‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant follicle‐stimulating hormone (rFSH) 150 IU
Study: 15844695
Drug: HCl infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCl infusion
Study: 7845419
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of miconazole 55 mg/g denture lacquer (single application)
Study: 7845419
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available miconazole 2% gel (applied four times daily for 2 weeks)
Study: 2840035
Drug: Tegafur 600
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur 600 mg p.o. for 8 weeks followed by 4 weeks rest (4 courses)
Study: 27647222
Drug: Dose-dense TCF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense TCF regimen with 30% dose reduction
Study: 27647222
Drug: Dose-dense TCF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense TCF regimen without dose reduction
Study: 24820281
Drug: Pregabalin combined
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin combined with intrathecal sufentanil infusion
Study: 24820281
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with intrathecal sufentanil infusion
Study: 24820281
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine sulfate controlled‐release tablet
Study: 20804445
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg + metformin XR
Study: 20804445
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + metformin XR
Study: 18404537
Drug: Ascorbate pre-treatment
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbate pre-treatment
Study: 10641162
Drug: Ciprofloxacin beta-cyclodextrin
Normalized name: Sulfobutylether-beta-cyclodextrin
DrugBank: Sulfobutylether-beta-cyclodextrin (DB18607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin beta-cyclodextrin inclusion complex dental implants
Study: 8890721
Drug: Intranasal GH
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GH 0.05 IU/kg
Study: 8890721
Drug: Intranasal GH
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GH 0.10 IU/kg
Study: 8890721
Drug: Intranasal GH
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal GH 0.20 IU/kg
Study: 8890721
Drug: Subcutaneous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GH 0.10 IU/kg
Study: 8890721
Drug: Intravenous GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous GH 0.015 IU/kg
Study: 3937598
Drug: CP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP (cyclophosphamide 1 g/m2 plus cisplatin 60 mg/m2)
Study: 3937598
Drug: HCAP (hexamethylmelamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCAP (hexamethylmelamine 150 mg/m2/day X 7, cyclophosphamide 400 mg/m2, doxorubicin 30 mg/m2, and cisplatin 60 mg/m2)
Study: 20507398
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg loading dose at week 0 followed by adalimumab 40 mg eow starting at week 2
Study: 20507398
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg eow
Study: 10204812
Drug: Bed rest,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bed rest, diet control, and antihypertensive drug (control group)
Study: 7491697
Drug: BT563 (anti-CD25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT563 (anti-CD25 mAb), cyclosporine, and steroids
Study: 7491697
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and cyclosporine-steroids
Study: 7364141
Drug: Betnovate cream
Normalized name: Betnovate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betnovate cream (betamethasone 17‐valerate 0.1%)
Study: 28338208
Drug: CBCT technology
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBCT technology combined with conventional root canal therapy (control group)
Study: 21299274
Drug: Telephone-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive behavioral therapy (T-CBT) for 16 sessions over 20 weeks
Study: 21299274
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual through the CBOC
Study: 16732839
Drug: SQ sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SQ sumatriptan 6 mg
Study: 16732839
Drug: TMB 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMB 200 mg and DPH 25 mg (TMB/DPH)
Study: 15616486
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic eye drops, a pacifier, plus three doses of 24% sucrose
Study: 15616486
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic eye drops, a pacifier, plus three doses of sterile water
Study: 8985627
Drug: Topical 0.5%
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5% timolol gel
Study: 8985627
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release acetazolamide
Study: 2888417
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine (MST 30)
Study: 2888417
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg lormetazepam (Noctamid)
Study: 22527424
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical imiquimod cream
Study: 22527424
Drug: Post-imiquimod therapy
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-imiquimod therapy (antibiotic creams, topical steroids, emollients)
Study: 18347392
Drug: Racol (omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racol (omega-3 fatty acid-containing diet) at a maximum dose of 600 mL/day during CRT
Study: 12749508
Drug: Repaglinide 1
Normalized name: repaglinide 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 1 mg/d
Study: 12749508
Drug: Glimepiride 1
Normalized name: glimepiride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 1 mg/d
Study: 29282469
Drug: Esketamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (all doses combined)
Study: 25158897
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 5 ml (25 mg/ml) tranexamic acid (TXA) and 5 ml analgesic containing epinephrine (3 μg/ml) injected at several points into the posterior capsule before installation of the prosthesis; 10 ml TXA and 10 ml analgesic containing epinephrine injected into the periosteum, synovium, joint capsule, tendons, and deep fascia before tourniquet release; TXA solution (20 ml) injected into the articular cavity after wound closure; drainage tube clamped for 4 h.
Study: 25158897
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Injection of analgesic containing epinephrine into soft tissue, control of active bleeding, and clamping of the drainage tube for 4 h only.
Study: 24654216
Drug: Methylphenidate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (25 mg daily)
Study: 7985255
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of terbutaline (2, 4, and 6 mg)
Study: 2532229
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (40 micrograms three times daily)
Study: 2532229
Drug: Fenoterol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.2 mg three times daily)
Study: 1128571
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of cholylglycine at a dose of 5 mumoles per kilogram
Study: 26236925
Drug: peg-interferon/ribavirin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg-interferon/ribavirin treatment for 12 weeks followed by 48 weeks for cEVR patients (Group A)
Study: 26236925
Drug: peg-interferon/ribavirin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg-interferon/ribavirin treatment for 12 weeks followed by 72 weeks (Group B1)
Study: 26236925
Drug: peg-interferon/ribavirin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: peg-interferon/ribavirin treatment for 12 weeks followed by 96 weeks (Group B2)
Study: 23179471
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (generic citalopram 20 mg)
Study: 23179471
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (branded citalopram 20 mg)
Study: 21502083
Drug: Valganciclovir 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir 900 mg daily for 8 weeks
Study: 10545787
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) and leucovorin (LV) administered as a 14-day continuous infusion according to a flat or three different chronomodulated rhythms
Study: 320494
Drug: Dantrium (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dantrium (up to 800 mg for 14‐16 days)
Study: 25974277
Drug: Control blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control blocks + intravenous (IV) dexamethasone (4 mg)
Study: 25974277
Drug: Control blocks
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control blocks + IV buprenorphine (150 μg) + IV dexamethasone
Study: 15046282
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 30% glucose
Study: 9776154
Drug: Intraoperative irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative irrigation with 10 mL 0.5% bupivacaine in 500 mL saline
Study: 28988173
Drug: Topical DPCP
Normalized name: DPCPX
DrugBank: DPCPX (DB12946)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DPCP therapy for up to 12 months
Study: 28988173
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod therapy for up to 12 months